Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BITR2101 in Relapsed/Refractory Non-Hodgkin Lymphoma
NCT06385522Phase 1Not yet recruiting
- Sponsor
- Boston Immune Technologies and Therapeutics
- Start
- Aug 2025
- Primary completion
- Jun 2026
- Modality
- Monoclonal Antibodies
01
Overview
Phase 1, open-label, single-arm trial of BITR2101 in non-Hodgkin lymphoma (NHL), cutaneous T-cell lymphoma (CTCL) and peripheral T-cell lymphoma (PTCL), sponsored by Boston Immune Technologies and Therapeutics. Primary endpoint: Safety and Tolerability to determine Maximum Tolerated Dose (MTD) and Recommended Dose for Expansion (RDE) up to 2 years. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
BITR2101
03
Conditions
non-Hodgkin lymphoma (NHL)cutaneous T-cell lymphoma (CTCL)peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT06385522.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06385522.